Sign In
Buy JNJ
$239.08
+7.79 (+3.37%)
At Close: Jun 23, 2026
Our 10 Favorite Stocks for 2023
06:55pm, Friday, 16'th Dec 2022
Our 10 favorites from last year handily beat the market. Why we now like Alphabet, Bank of America, Medtronic, and seven others.
FDA Delays Decision on AstraZeneca (AZN), Merck's Lynparza sNDA
04:38pm, Friday, 16'th Dec 2022 Zacks Investment Research
The FDA extends the review period of AstraZeneca (AZN)/Merck's filing seeking label expansion for Lynparza's indication in prostate cancer. The FDA intends to use this time to review the submission.
Want $250 in Passive Income? Buy These 2 Dividend Kings and Wait
02:53pm, Friday, 16'th Dec 2022 The Motley Fool
These companies will work hard to grow your base of passive income.
Warren Buffett Loves These Stocks. Should You Buy Them Before 2023?
10:30am, Friday, 16'th Dec 2022 The Motley Fool
There's a lot more ahead for these market giants.
5 Phenomenal Stocks in Warren Buffett's Secret Portfolio That Are Screaming Buys in 2023
10:06am, Friday, 16'th Dec 2022 The Motley Fool
The Oracle of Omaha's $5.9 billion hidden portfolio is home to five amazing companies that are ripe for the picking.
Want $250 in Passive Income? Buy These 2 Dividend Kings and Wait
09:53am, Friday, 16'th Dec 2022
These companies will work hard to grow your base of passive income.
Warren Buffett Loves These Stocks. Should You Buy Them Before 2023?
05:30am, Friday, 16'th Dec 2022
There's a lot more ahead for these market giants.
5 Phenomenal Stocks in Warren Buffett's Secret Portfolio That Are Screaming Buys in 2023
05:06am, Friday, 16'th Dec 2022
The Oracle of Omaha's $5.9 billion hidden portfolio is home to five amazing companies that are ripe for the picking.
Zacks Industry Outlook Highlights Johnson & Johnson, Novo Nordisk, Merck and AstraZeneca
10:00am, Thursday, 15'th Dec 2022 Zacks Investment Research
Johnson & Johnson, Novo Nordisk, Merck and AstraZeneca have been highlighted in this Industry Outlook article.
4 Large Drug Stocks to Watch in a Booming Industry
01:34pm, Wednesday, 14'th Dec 2022 Zacks Investment Research
Drug/biotech companies are likely to see significant advances in innovation in 2023. In the Large-Cap Pharmaceuticals industry, Johnson & Johnson (JNJ), Novo Nordisk (NVO), Merck (MRK) and AstraZeneca
2 Top Dividend Kings to Buy for the Long Haul
01:15pm, Wednesday, 14'th Dec 2022 The Motley Fool
No matter how much changes, these two healthcare giants keep performing.
4 Large Drug Stocks to Watch in a Booming Industry
09:47am, Wednesday, 14'th Dec 2022
Drug/biotech companies are likely to see significant advances in innovation in 2023. In the Large-Cap Pharmaceuticals industry, Johnson & Johnson (JNJ), Novo Nordisk (NVO), Merck (MRK) and AstraZeneca
Johnson & Johnson to Host Investor Conference Call on Fourth-Quarter Results
04:30pm, Tuesday, 13'th Dec 2022
NEW BRUNSWICK, N.J.--( BUSINESS WIRE )--Johnson & Johnson (NYSE: JNJ) will host a conference call for investors at 8:30 a.m. (Eastern Time) on Tuesday, January 24th to review fourth-quarter results. J
Amgen wins battle for Horizon Therapeutics, bolstering its rare-disease portfolio
12:47pm, Tuesday, 13'th Dec 2022 MarketWatch
Amgen Inc. is acquiring Dublin-based Horizon Therapeutics in a roughly $28 billion deal that is the biggest in the healthcare sector in 2022.
Reliable Passive Income: an Analysis on Dividend Kings
12:33pm, Tuesday, 13'th Dec 2022 The Motley Fool
A Dividend King is any stock that has increased its dividend for 50+ cosecutive years, doubling that of a Dividend Aristocrat.
